Form 4: CG Oncology's Chief Medical Officer Granted Stock Options

Vijay Kasturi, Chief Medical Officer of CG Oncology, Inc., was granted employee stock options on April 15, 2025.

Summary

• Vijay Kasturi, the Chief Medical Officer of CG Oncology, Inc., received employee stock options.
• The transaction occurred on April 15, 2025.
• The granted options are for 203,868 shares of common stock at an exercise price of $20.11 per share.
• The options vest monthly over a four-year period, commencing on April 15, 2025, contingent upon continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The granting of stock options aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The vesting schedule suggests a long-term commitment from the Chief Medical Officer to CG Oncology.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates

Keywords

stock options, CG Oncology, Vijay Kasturi, Chief Medical Officer, equity, Form 4, insider trading